Overview of Detrax

Quick Facts

Property	Description
Active ingredient	Levamisole (often as Levamisole HCl)
Forms	Tablet, Oral liquid, Injectable solution
Pharmacological class	Anthelmintic, Immunomodulator
General purpose	Eliminates parasitic worms and supports immune function
Origin	Synthetic (Imidazothiazole derivative)

Detrax is a medicine defined by its active pharmaceutical ingredient, Levamisole, a versatile compound known for its dual therapeutic roles. Its fundamental purpose is to address parasitic infestations and support the body's general immune function, classifying it as both an anthelmintic drug and an immunomodulator. Levamisole is classified within the Anatomical Therapeutic Chemical (ATC) system under the Antinematodal Agents group.

Detrax: Identity, Composition, and Origin

Detrax is a medicine based on the International Nonproprietary Name (INN) substance Levamisole, which is frequently formulated using the highly water-soluble Levamisole Hydrochloride (Levamisole HCl) salt. Levamisole is a strictly synthetic chemical entity, belonging to the imidazothiazole derivative class; it is a laboratory-created molecule with a defined structure rather than a naturally sourced compound. This pharmaceutical is typically available as a single-ingredient product, and the Levamisole INN is often associated with popular trade names like Ketrax and Ergamisol.

What Pharmacological Class Does Detrax Belong To?

Detrax is categorized by a dual pharmacological classification, serving primarily as an anthelmintic drug (anti-worm agent) and secondarily as an immunomodulator (a substance that regulates immune function). Levamisole has the capacity to restore depressed immune responses by modulating T-cell activity, demonstrating its systemic role beyond direct parasite action. The medicine is clinically recognized for its ability to modulate host immunity, a key feature that differentiates it from older anti-worm compounds. This dual nature allows for a therapeutic benefit in the expulsion of parasitic organisms from the body while simultaneously offering the capacity to help restore depressed immune functions.

How is Levamisole Different from Related Compounds?

Levamisole is chemically distinct because it is the pure, therapeutically active Levo-isomer of the less specific racemic compound known as Tetramisole. The anthelmintic and immunomodulatory activity is predominantly attributed to this specific Levamisole molecular configuration (the S-enantiomer), providing a more focused and targeted pharmacological action compared to the mixture of isomers found in Tetramisole. This specific stereochemistry is essential for the drug’s intended biological effect, reinforcing the importance of its pure form.

Regulatory References

What side effects are possible with Detrax?

Possible Side Effects and Safety Information for Detrax

Adverse reaction information for Detrax is based on regulatory documents that classify unwanted effects according to standardized system-organ classes and frequency of occurrence (e.g., very common, common, uncommon, rare, very rare, not known). These classifications are derived from clinical trials and ongoing post-marketing surveillance data.

Key Safety Profile Summary

Adverse Reaction Category	Scope and Definition
Common Adverse Reactions	Typically minor and often dose-related effects (Type A), such as gastrointestinal upset or mild headache, reported in official labeling at a frequency of ge 1/100 to < 1/10.
Serious Adverse Reactions	Adverse events that are life-threatening, result in hospitalization, cause significant or permanent disability, or lead to death, as formally documented in regulatory safety analyses.
System-Organ Classes	Effects are categorized by the anatomical system they involve, such as Nervous system disorders, Gastrointestinal disorders, and Skin and subcutaneous tissue disorders.

Population-Specific Considerations and Restrictions

Safety data may indicate specific requirements for monitoring in certain patient groups, such as those with pre-existing hepatic or renal impairment, which necessitate dose adjustments or intensified monitoring. The official labeling establishes specific Contraindications, which are conditions where Detrax must not be used due to an unacceptable risk, and Warnings and Precautions, which detail situations requiring particular caution or risk mitigation, such as potential drug interactions or the risk of Severe Cutaneous Adverse Reactions (SCARs). The documentation also addresses known risks related to pregnancy and lactation as dictated by governmental regulatory authorities (e.g., FDA, EMA).

Regulatory documentation mandates continuous safety surveillance throughout the drug's life cycle to detect and assess new adverse event signals, defining the overall known risk profile.

Overdose and Emergency Response

Detrax Overdose and When to Seek Help

Official regulatory information describes Detrax (Levamisole) overdosage as having the potential for severe and life-threatening consequences. Overexposure may present with acute non-specific symptoms including nausea, vomiting, diarrhea, headache, dizziness, and confusion. More severe clinical signs, often described as resembling cholinomimetic toxicity, such as salivation and muscle tremors, have also been documented.

The primary concerns highlighted in regulatory documents relate to serious systemic outcomes, particularly hematological toxicity (e.g., agranulocytosis, leukopenia) and severe neurological effects such as convulsions and leukoencephalopathy.

Required Emergency Actions

Official labeling mandates that patients seek immediate medical advice if overdose is suspected or if symptoms of severe toxicity, such as signs of a blood disorder (e.g., fever, sore throat) or severe neurological disturbances, appear. There is no specific antidote known for Levamisole toxicity. Clinical management in a healthcare setting is strictly symptomatic and supportive, which may involve procedures like gastric lavage if performed early after ingestion. The use of atropine may be considered to address signs of anticholinesterase activity, and continuous monitoring of vital signs is required during management.

Therapeutic Uses of Detrax

Detrax is primarily intended to provide short-term symptomatic support and comfort across various clinical contexts. It is commonly used when short-term symptomatic assistance is needed, helping to manage phases when symptoms related to heightened physiological activity become intense or disruptive. The medication offers symptomatic relief that may assist patients in coping more steadily with difficult episodes.

Key Therapeutic Applications

The therapeutic category of Detrax may be relevant in clinical settings that involve acute or unstable symptom patterns.

Detrax is generally used to address symptom clusters that may appear suddenly, providing support that helps ease the overall symptom burden during episodes of heightened discomfort. It is applied in addressing symptoms related to physical discomfort and conditions involving episodic or fluctuating manifestations. The product is considered relevant for managing symptoms that create noticeable physiological strain and interfere with daily comfort. This supportive action is relevant in contexts marked by increased discomfort or tension.

“Detrax is generally used when short-term symptomatic assistance is needed.”

Quick Fact: Supportive management for symptoms associated with acute or episodic changes.

Regulatory References

NIH Bookshelf overview on Dextran's clinical uses

Eligibility and Restrictions for Use

Detrax (Levamisole) eligibility is strictly defined by regulatory documents, distinguishing between permitted use, conditional use, and absolute contraindications. Adults and pediatric patients are generally eligible for use under labeled conditions. However, the medicine is contraindicated and must not be used by individuals with a documented hypersensitivity to the drug or by patients with pre-existing blood disorders. Use is also prohibited shortly before or after administering organophosphorus compounds.

Specific life stages impose restrictions: use is generally not recommended for pregnant women (FDA Category C) and the World Health Organization advises against use by breastfeeding women. Use requires caution in patients with hepatic impairment and is not recommended in those with severe kidney diseases. Caution is also specified for patients with comorbidities like rheumatoid arthritis and epilepsy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Detrax (Levamisole) interaction information is defined by restrictions on concomitant use, mandatory timing rules, and specific exposure alterations documented in regulatory prescribing information. Interaction constraints are formally established by official health authorities to manage co-administration risks.

Documented Interaction Patterns

Substance / Condition	Official Interaction Description / Classification
Alcohol (Ethanol)	Causes a severe disulfiram-like reaction, representing a critical pharmacodynamic and metabolic constraint.
Organophosphorus compounds	Co-administration is prohibited unless separated by a mandatory period of 14 days (timing-based restriction).
Warfarin and Phenytoin	Levamisole may increase the effects or increase the toxicity of these co-administered medicines.
Ivermectin and Albendazole	Levamisole alters the bioavailability of other anthelmintics, specifically increasing exposure to Ivermectin and decreasing exposure to Albendazole.

Population-Specific Interaction Notes

The regulatory label includes specific use restrictions where patient status heightens interaction risk. Levamisole is formally contraindicated in individuals with pre-existing blood disorders or severe renal impairment. These conditions preclude use due to potential compounding of adverse effects tied to the medicine's clearance and hematological profile, establishing an interaction-context restriction.

Mechanism of Action

Detrax, also known as Dexrazoxane, functions primarily as an intracellular chelating agent, following its conversion from a pro-drug to the active compound, ADR-925. This active metabolite, a ring-opened bidentate chelator, accumulates in cardiac myocytes. The biological target of ADR-925 is free or weakly-bound transition metal ions, specifically iron (Fe^3+). The interaction type is a chelation, which sequesters the metal ion and prevents its participation in downstream molecular and intracellular pathways. By chelating intracellular iron, Detrax interferes with the iron-catalyzed generation of reactive oxygen species (ROS), such as superoxide and hydroxyl radicals, which are typically initiated via a Fenton-like reaction. This interruption of the oxidative stress cascade represents a key downstream cascade modification. Additionally, Detrax acts as an inhibitor of topoisomerase IIbeta (TOP2beta) enzyme activity in the cardiac tissue. The systemic physiological consequence of these dual actions is the modulation of myocyte integrity by mitigating oxidative damage and maintaining nucleic acid stability.

Dosage and Administration Information

How to Use Detrax: Official Administration Guidelines

The administration of Detrax (Levamisole) is governed by specific instructions defining two distinct usage patterns: a short-term, single-course regimen for anthelmintic use and a long-term, intermittent cyclical regimen for its immunomodulatory use.

Administration Scope	Detail
Route of administration	Administration is oral only, utilizing available tablet or liquid dosage forms.
Dosing schedule	For short-term anthelmintic use, the adult regimen is a single dose typically between 120 and 150 mg. The long-term adjuvant regimen involved a lower dose (e.g., 50 mg) taken three times daily.
Age-group administration rules	Pediatric dosing is determined by a body weight calculation (e.g., 2.5 to 3 mg per kg body-weight). Use is restricted for patients with advanced hepatic or renal impairment.
Missed-dose rules	If a scheduled dose is missed, it should be skipped, and the regular dosing schedule resumed; doses must not be doubled to compensate.
Special procedural conditions	Alcohol consumption is strictly prohibited during the entire administration period and for at least 24 hours following intake.

Connection to the Overall Use Protocol

These instructions standardize the required oral route and define the two separate dosage protocols—a single fixed-dose schedule versus a cyclical schedule—that determine the administration pattern based on the intended duration of use. The protocol also establishes precise constraints regarding dose omission and concurrent substance use, which must be followed exactly.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Detrax (Levamisole)

Evidence for Use in Parasitic Worm Infections (Anthelmintic Action)

Detrax was studied extensively in the context of its initial investigation, with research exploring the clearance rates of certain nematode parasites. The research included short-term randomized controlled trials (RCTs) and efficacy studies. Historically, regulatory bodies noted consistency in the clearance patterns for susceptible species when studied under controlled conditions. This body of research helps show what has been observed so far in terms of the compound’s activity against these infections.

However, the majority of this evidence is historical. Research provides context but not individual predictions. Data for certain subgroups, such as those with specific comorbidities, were limited in the core regulatory record.

Evidence for Use in Steroid-Sensitive Nephrotic Syndrome (SSNS)

Research has studied the investigation of Detrax in patients with steroid-sensitive nephrotic syndrome (SSNS), primarily in children. The studies included controlled trials, often randomized and double-blind. Researchers monitored outcomes related to disease activity, specifically assessing the rate at which the condition relapsed (recurring proteinuria) and the total amount of steroid medication required by the patients.

What the studies reported: Findings described observed patterns where relapse frequency measurements differed during the study period when compared to the control group or baseline measurements in certain pediatric cohorts. Furthermore, studies reported measurements indicating patterns where cumulative exposure to steroid medication differed in some cohorts. Research provides insight into short-term changes in these specific pediatric populations.

Outcomes Examined in Clinical Trials for Nephrotic Syndrome

Studies examined patient-reported outcomes describing perceived discomfort and functional limitations related to the condition. The core focus of the clinical trials was to examine measured outcomes related to the status of disease remission, evaluating outcomes reflecting daily functioning, and monitoring physiological strain related to the use of corticosteroids.

What remains uncertain: Research data are limited for adults with frequently relapsing or steroid-dependent SSNS, as the majority of trials focused on children. Comparative evidence against some other therapeutic options is lacking.

Historical Evidence for Use in Colon Cancer

Detrax was evaluated in large-scale, long-term randomized controlled trials as a part of a combination regimen for adult patients with Stage III colon carcinoma. The research monitored outcomes linked to long-term survival, specifically examining disease-free survival (DFS) and overall survival (OS) over multi-year periods. Studies reported measurements related to survival time and recurrence rates in the combined treatment group compared to the control group during the historical study period.

This body of research is historical and no longer reflects the current standard of care for colon cancer. The long-term research described specific safety patterns documented for the high-dose regimen studied.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Detrax (FAQ)

Q: Where can I find the official prescribing information (package insert) for Detrax?

The official prescribing information, patient guides, and safety details are available through regulatory agency websites. These sources, such as the FDA DailyMed or EMA SmPC documents, contain the most complete and authoritative information about the medicine. Reputable, government-linked drug information resources also provide summaries of this data.

Q: Is Detrax safe for lifelong use?

Regulatory documents state that serious, long-term complications have been associated with its use, particularly with extended or repeated exposure. These complications include severe blood disorders (agranulocytosis) and a neurological condition known as leukoencephalopathy. These safety concerns led to the drug’s withdrawal from the market in some countries.

Q: Is Detrax generally appropriate for use in older adults (seniors)?

Official product information indicates that the medicine has been studied in elderly patients. It is not expected to cause different side effects or problems in older people than it does in younger adults. As with any medication, use in seniors is typically reviewed by a healthcare provider.

Q: Does Detrax cause weight gain or weight loss?

According to the official product information, loss of appetite (anorexia) is listed among the reported side effects. This can sometimes lead to rapid or unexpected weight loss. Regulatory guidance recommends reporting persistent changes in appetite or rapid weight loss to a healthcare professional.

Q: I feel dizzy and have a headache when I first start taking Detrax. Is this normal, and how long does it last?

Official safety data confirms that both dizziness and headache are commonly reported side effects. While the exact duration of these symptoms is not specified in regulatory documents, some side effects may lessen as the body adjusts to the medicine. Regulatory guidance suggests these symptoms be discussed with a healthcare professional if they persist or become severe.

Q: Are the side effects temporary, or do they last for the entire duration of treatment?

Studies and official information indicate that most side effects are temporary and generally harmless. These effects are often expected to resolve shortly after the medicine is discontinued. However, regulatory documents note that rare, serious side effects may necessitate evaluation by a healthcare provider.

Q: What are the signs of a serious reaction that require me to call my doctor immediately?

Signs of a serious reaction listed in official documents include fever or chills, unusual bleeding or bruising, sores in the mouth, and signs of infection. Nervous system issues such as confusion or convulsions (seizures) should also be reported immediately.

Q: Does Detrax affect my sleep or make me feel tired or low-energy?

Official safety information reports that effects on the nervous system have been observed. Reported side effects include drowsiness, trouble sleeping (insomnia), unusual tiredness, and fatigue. These effects are monitored as part of the known risk profile.

Q: Can Detrax affect my mood or emotional state (e.g., irritability, depression)?

Official safety data indicates that changes in mood and emotional state have been reported. These can include anxiety, nervousness, irritability, and mental depression. Such effects are listed under the documented side effects of the medicine.

Q: What are the long-term safety concerns or risks I should be aware of?

Regulatory warnings have highlighted the risk of serious, long-term complications, including a condition called leukoencephalopathy and severe blood disorders like agranulocytosis. These known risks led to its withdrawal from the market in the US and Canada.

Q: Is Detrax safe for people with pre-existing heart conditions?

Scientific literature indicates that the drug can influence cardiovascular function parameters. Official information suggests that the presence of pre-existing heart conditions may increase the risk for cardiac complications. Official information suggests its use in these patients may require evaluation by a healthcare provider.

Q: Is there a potential for drug dependence or withdrawal when stopping Detrax?

Regulatory guidance and patient information state that the medicine is not known to cause dependency or addiction. However, regulatory guidance states that discontinuation of the medicine should be discussed with a healthcare professional.

Q: What is the best time of day to take Detrax?

The medicine is generally prescribed to be taken once a day. Although sometimes recommended in the morning for convenience, a specific time can be chosen if it helps ensure the patient takes the medication regularly. The administration schedule should align with the directions provided by a healthcare provider.

Q: Should I take Detrax with food or on an empty stomach?

Some official patient information indicates that there are no known interactions between this drug and food. However, general guidance recommends discussing the conditions of use, including taking the medicine with food, with a healthcare professional.

Q: Is there a generic version of Detrax available?

Levamisole is the generic name of the active substance in Detrax. This ingredient is available under its generic name and various trade names internationally, and it is listed on the World Health Organization's List of Essential Medicines.

Q: Is Detrax considered a controlled substance?

Levamisole is not listed as a controlled substance by the US DEA or similar major international regulatory bodies. However, its widespread misuse as an adulterant in illegal drugs has been documented by law enforcement and public health agencies.

Q: Is there ongoing research for new uses of Detrax (e.g., cancer, autoimmune disease)?

Yes. Due to its known immunomodulatory (immune-regulating) properties, there is ongoing research and clinical trials investigating its potential use in conditions like aplastic anemia, nephrotic syndrome, and various cancers.

Q: What is the onset of action (how quickly does it work)?

In its authorized use as an anthelmintic (anti-worm agent), it is described as a fast-acting agent. It paralyzes the parasitic worm's musculature within seconds of contact, and the worms are typically expelled from the body within 24 hours of administration.

Q: What is the drug's half-life?

Official pharmacokinetic data indicates that the plasma elimination half-life of the drug itself is 3–4 hours. However, it is important to note that a major, active metabolite of the drug has a longer half-life of 16 hours.

Q: Was Detrax developed and approved in the US/EU, and when?

The drug was invented in Belgium by Janssen Pharmaceuticals in 1966. It was approved by the FDA in the United States in 1990 for use as an adjuvant treatment for colon cancer. Its use and approval status have changed over time.

Q: How does Detrax work in the body?

The drug has two main documented roles. As an anthelmintic, it works by stimulating specific receptors on the parasitic worm, causing rapid paralysis. It also acts as an immunomodulator, meaning it helps to regulate or restore depressed functions of the human immune system.

Q: What is the current FDA/EMA/MHRA position on Detrax?

The drug was withdrawn from the US and Canadian markets due to safety concerns several years ago. In the European Union, it remains authorized in select countries for parasitic worm infections, but the EMA is currently conducting a safety review regarding the risk of a serious neurological condition.

How should Detrax be stored and disposed of?

Official Storage and Disposal Requirements

Official regulatory information for Detrax (Levamisole) mandates specific conditions to ensure product stability and safety. This medication must be kept in a cool and dry place, with temperature storage generally required to be below 25 C (77 F). To maintain efficacy, the product must be protected from light and stored in its original container with the lid tightly closed, and it should be protected from frost.

Security and Disposal

Safety guidelines explicitly require that Detrax be stored out of the reach of children and kept locked up. Regarding disposal, the official instructions prohibit the product from being discarded into wastewater systems or drains to avoid environmental release. Any unused or expired Detrax must be disposed of strictly in accordance with local regulatory requirements for pharmaceutical waste.

Detrax